TP53缺失的初诊多发性骨髓瘤伴颅内侵犯2例  

Intracranial involvement in newly diagnosed multiple myeloma with TP53 deletion: Two case reports

作　　者：曲双[1] 廖丽昇[1] 谢颖[1] 郑志海[1] 陈碧云[1] QU Shuang;LIAO Lisheng;XIE Ying;ZHENG Zhihai;CHEN Biyun(Department of Hematology,Fujian Provincial Hospital、Provincial Clinical Medicine College,Fujian Medical University,Fuzhou 350001,China)

机构地区：[1]福建医科大学附属省立临床医学院,福建省立医院血液科,福州350001

出　　处：《中南大学学报（医学版）》2018年第11期1272-1275,共4页Journal of Central South University ：Medical Science

基　　金：福建省自然科学基金(2015J05140);福建省中青年骨干人才培养项目(2016-ZQN-11);福建省立医院优秀青年医师项目(2014061).

摘　　要：两例初治多发性骨髓瘤伴颅内侵犯的患者起病均以中枢神经系统功能受损为临床表现,颅骨受到破坏的同时存在多发硬膜侵犯。伴TP53缺失的遗传学异常与颅内侵犯的相关性,尚无定论。患者均接受含硼替佐米、阿霉素的多药联合方案,取得良好的短期疗效,与文献报道符合。TP53缺失的初治多发性骨髓瘤伴颅内侵犯预后不良。以硼替佐米为基础的强化学药物治疗方案联合自体或异基因造血干细胞移植有望提高临床疗效。We report two rare cases of multiple myeloma (MM)with dural intracranial disease and TP53 deletion.The two patients presented with skull lytic lesion and dural involvement of myeloma.The association between intracranial involvement in MM and TP53 deletion has not been determined. The two patients received bortezomib-based intensive induction and got good response,just as that reported in literature.MM presenting with dural intracranial disease and TP53 deletion at diagnosis is associated with poor outcome.Multi-drug regime containing bortezomib followed by autologous or allogeneic stem cell transportation would improve the prognosis.

关 键 词：骨髓瘤 TP53 颅内侵犯 

分 类 号：R733.3[医药卫生—肿瘤]